Compare Coursera Inc (COUR) vs Gilead Sciences, Inc. (GILD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Coursera Inc vs Gilead Sciences, Inc. — how do they compare? Coursera Inc trades at $5.54 (market cap $1.50B), while Gilead Sciences, Inc. trades at $136.42 (market cap $168.35B). The key difference: Gilead Sciences, Inc. is far larger — about 112.2× Coursera Inc's market cap, and Gilead Sciences, Inc. pays a 2.42% dividend while Coursera Inc pays none. Which is the better fit depends on your goals.
| COUR | GILD | |
|---|---|---|
Market Cap | $1.50B | $168.35B |
Sector | Consumer Staples | Health |
52-Week High | $12.20 | $155.80 |
52-Week Low | $5.09 | $110.56 |
Enterprise Value | $759.54M | $191.42B |
Dividend Yield | — | 2.42% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
COUR trades at $5.76, down 0.86% today, with a neutral technical signal. Revenue grew to $757.5M in 2025, but net income remains negative at -$51M. The company recently beat Q2 2026 EPS estimates at $0.17 versus $0.10 expected. Positive cash flow from operations of $108.7M in 2025 supports liquidity, while a $100M investment in LearnVector highlights strategic AI focus.
Outlook is mixed: analyst consensus is bullish with a $7.70 price target (34% upside), but persistent losses and competitive pressures pose risks. The stock offers growth potential if profitability improves, yet high SG&A costs and integration challenges from the Udemy acquisition require monitoring.
Gilead Sciences (GILD) trades at $133.06, down slightly by 0.11% today, with a bullish technical signal supported by moving averages. The company reported strong Q2 2026 revenue growth of 8% year-over-year, beating estimates, though a net loss of $6.75 per share resulted from acquisition-related costs. Analyst consensus is strongly bullish with a $151.22 price target, and recent news highlights robust HIV drug sales and pipeline progress.
The outlook for GILD is positive, driven by raised 2026 guidance and HIV franchise strength, but risks include patent cliffs by the mid-2030s and integration challenges from acquisitions. Investors should weigh the high valuation multiples against growth potential, with the stock offering upside if execution continues to exceed expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Coursera Inc
Coursera Inc is a global online learning platform that offers anyone, anywhere access to online courses and degrees from world-class universities and companies. It combines content, data, and technology into a single, unified platform that is customizable and extensible to both individual learners and institutions. The platform will contain a catalog of high-quality content and credentials, content developed by leading university and industry partners, data and machine learning drive personalized Learning, effective marketing, and skills Benchmarking and others.
Read more on COUR →About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →
